Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Operating Cash Flow to Debt Ratio 3 year CAGR for the quarter ending September 19, 2024

Agios Pharm Operating Cash Flow to Debt Ratio 3 year CAGR is NA for the quarter ending September 19, 2024. The operating cash flow to debt ratio measures the ability of a company's operating cash flow to cover its total debt obligations. It is calculated by dividing the operating cash flow by the total debt. This ratio provides insights into the company's ability to generate cash flow from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating cash flow relative to the level of debt, suggesting potential financial strength and debt servicing capability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends